Log In
BCIQ
Print this Print this
 

SER-301

  Manage Alerts
Collapse Summary General Information
Company Seres Therapeutics Inc.
Description 
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease
Regulatory Designation
PartnerNestle S.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,880.0M

$120.0M

$1,760.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/11/2016

$1,880.0M

$120.0M

$1,760.0M

Get a free BioCentury trial today